MedTrace Logo

Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study

NCT05912387 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-02-27

No results posted yet for this study

Summary

PSC is a liver disease that has no medical cure. Patients with PSC are at a greatly increased risk of cancer and infection. Additionally, many patients require a liver transplant. Progress towards a cure has been severely limited by an incomplete understanding of why patients develop PSC. The investigators aim to close this gap by conducting a pilot human study in patients with PSC, using statin therapy as a model

Conditions

  • Primary Sclerosing Cholangitis
  • Inflammatory Bowel Diseases

Interventions

DRUG

Rosuvastatin

Rosuvastatin 20 mg tablet once daily by mouth

Sponsors & Collaborators

Principal Investigators

  • Sidhartha Sinha, MD · Stanford University

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-31
Primary Completion
2027-05-31
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05912387 on ClinicalTrials.gov